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Tumour necrosis factor-α-induced loss of intestinal barrier
function requires TNFR1 and TNFR2 signalling in a mouse
model of total parenteral nutrition
Yongjia Feng and Daniel H. Teitelbaum
Section of Pediatric Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI, USA
Key points
• Total parenteral nutrition (TPN) is critical for patients who cannot tolerate enteral nutrition.
However, TPN-associated loss of barrier function leads to an increase in enterically derived
pathogens that may harm the patient.
• Tumournecrosis factor-α (TNF-α) is involved in the dysregulationof intestinal barrier function
in many animal models.
• Themousemodel ofTPNprovides an excellent, non-destructive approach to examine epithelial
barrier dysfunction.
• Tumour necrosis factor-α is shown to be a major mediator of epithelial barrier dysfunction
using this TPN model.
• Tumour necrosis factor-α signalling is reliant on both the TNFR1 and TNFR2 pathways to
effect epithelial barrier dysfunction.
• Anti-TNF treatment protected against TPN-associated epithelial barrier dysfunction andmight
prove to be a viable future clinical approach.
Abstract Tumour necrosis factor-α (TNF-α) has been reported to play a central role in intestinal
barrier dysfunction in many diseases; however, the precise role of the TNF-α receptors (TNFRs)
has not been well defined using in vivo models. Our previous data showed that enteral nutrient
deprivation or total parenteral nutrition (TPN) led to a loss of intestinal epithelial barrier function
(EBF), with an associated upregulation of TNF-α and TNFR1. In this study, we hypothesized that
TNF-α plays an important role in TPN-associated EBF dysfunction. Using a mouse TPN model,
we explored the relative roles of TNFR1 vs. TNFR2 in mediating this barrier loss. C57/BL6 mice
underwent intravenous cannulation and were given enteral nutrition or TPN for 7 days. Tumour
necrosis factor-α receptor knockout (KO) mice, including TNFR1KO, TNFR2KO or TNFR1R2
double KO (DKO), were used. Outcomes included small intestine transepithelial resistance (TER)
and tracer permeability, junctional protein zonula occludens-1, occludin, claudins andE-cadherin
expression. In order to address the dependence of EBF on TNF-α further, exogenous TNF-α and
pharmacological blockade of TNF-α (Etanercept) were also performed. Total parenteral nutrition
led to a loss of EBF, and this was almost completely prevented in TNFR1R2DKOmice and partly
prevented in TNFR1KO mice but not in TNFR2KO mice. The TPN-associated downregulation
of junctional protein expression and junctional assembly was almost completely prevented in the
TNFR1R2DKO group. Blockade of TNF-α also prevented dysfunction of the EBF and junctional
protein losses in mice undergoing TPN. Administration of TPN upregulated the downstream
nuclear factor-κB and myosin light-chain kinase (MLCK) signalling, and these changes were
almost completely prevented in TNFR1R2DKO mice, as well as with TNF-α blockade, but
not in TNFR1KO or TNFR2KO TPN groups. Tumour necrosis factor-α is a critical factor for
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TPN-associated epithelial barrier dysfunction, and both TNFR1 and TNFR2 are involved in EBF
loss. Nuclear factor-κB and MLCK signalling appear to be important downstream mediators
involved in this TNF-α signalling process.
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Introduction
Total parenteral nutrition (TPN), or the removal of
all enteral nutrients, is commonly used clinically for
patients who cannot tolerate nutrition through their
gastrointestinal tract. Despite being life sustaining, clinical
usage of TPN has led to an increase in enterically derived
pathogens, presumably due to a loss of epithelial barrier
function (Buchman et al. 1995). Maintenance of an
intact intestinal epithelial barrier is essential in preventing
intestinal penetration of luminal toxins, antigens and
bacteria. The importance of an intact epithelial barrier
function (EBF) has been appreciated by the association
of a loss of barrier function with several disease states
(Amasheh et al. 2010; Hering et al. 2011; Menard et al.
2012; Schumann et al. 2012). A principal contributor to
the regulation of the intestinal EBF is the integrity of the
epithelial tight junction (TJ) complex, which bridges the
interepithelial cell spaces and provides a strong deterrent
to the paracellular passage of nutrients, toxins and other
intraluminal substances (Mitic & Anderson, 1998; Mitic
et al. 2000; Aijaz et al. 2006). Pro-inflammatory signalling
clearly plays a critical role in breaking down TJ integrity
(Shen et al. 2006; Schwarz et al. 2007; Noth et al. 2011;
Cunningham&Turner, 2012; Petecchia et al. 2012;Watson
&Hughes, 2012). However, the predominant models used
to study loss of EBF have been epithelial injury models,
such as inflammatory bowel disease (Amasheh et al. 2009;
Arrieta et al. 2009; Edelblum & Turner, 2009; Mankertz
et al. 2009; Bereswill et al. 2010). The overt damage to
the epithelium in such models can confound the ability to
examine the fine interplay of between pro-inflammatory
signalling and TJ integrity.
A unique model of EBF loss is the mouse model
of enteral nutrient deprivation. In this model, mice
are sustained with TPN and have shown a significant
loss of EBF without destruction of the epithelium
(Sun et al. 2008; Feng et al. 2009). Although the
precise mechanisms that drive this EBF loss are not
completely known, researchers in our laboratory have pre-
viously demonstrated an upregulation of tumour necrosis
factor-α (TNF-α) and expression of its receptor TNFR1
within the small bowel mucosa in this TPN model.
These pro-inflammatory changes were associated with
a decline in intestinal epithelial cell (IEC) proliferation
and an increase in IEC apoptosis (Feng & Teitelbaum,
2012). Tumour necrosis factor-α has a central role in
many diseases associated with intestinal epithelial barrier
dysfunction, including inflammatory bowel disease (Baert
& Rutgeerts, 1999; Baert & Rutgeerts, 2000; Suenaert et al.
2002), intestinal ischaemia (Tamion et al. 1997; Taylor
et al. 1997) and graft-vs.-host disease (Brown et al. 1999).
Over the past two decades, a deeper understanding of
the mechanisms that lead to a TNF-α-induced loss of
EBF has been gained. Tumour necrosis factor-α, along
with other pro-inflammatory mediators, such as LIGHT
(lymphotoxin-like inducible protein that competes with
glycoprotein D for herpes virus entry on T cells) and
interleukin-1β (Schwarz et al. 2007; Al-Sadi et al. 2008,
2010), help tomediate this loss of EBF. Cytokine signalling
leads to phosphorylation of myosin light chain (MLC)
and a loss of zonula occludens-1 (ZO-1), as well as
an internalization of occludin within the cytoplasm
via incorporation into caveolin-1-containing vesicles
(Marchiando et al. 2010; Cunningham & Turner, 2012).
Previous work using in vitro models has suggested that
this signalling pathway is dependent on a TNFR2 pathway
(Wang et al. 2005). This is intriguing, and if this pathway is
the major mediator of loss of EBF it may be an important
target for future clinical therapies in conditions which
are associated with a loss of EBF, such as inflammatory
bowel disease. However, the in vitro approach of these
investigations may not fully represent modulation of EBF
within an in vivo setting.
Wehypothesized that the increasedexpressionofTNF-α
is a critical factor which contributes to TPN-associated
loss of intestinal barrier function and that TNF-α receptor
ligation plays an important role in this process. Our
present study demonstrated a critical role of TNF-α
signalling in the mechanisms which drive the loss of
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EBF in this mouse model of TPN. Using TNFR1R2
double knockout (DKO) and TNFR1 or TNFR2 single
knockout (KO) mice, this work demonstrates the novel
finding that both the TNFR1 and the TNFR2 signalling
pathways are critical for mediation of the loss of EBF in
this model. Blockade of TNF-α signalling was effective
at protecting EBF. These findings are important in that
this improved understanding of EBF loss may help to
direct future therapeutic options for patients dependent
on TPN as well as those who suffer from a loss of EBF
from other disease processes, such as inflammatory bowel
disease.
Methods
Animal model of parenteral nutrition
Male C57BL/6J specific pathogen-free mice (10–12 weeks
old; Jackson Laboratory, Bar Harbor, ME, USA)
were maintained in temperature-, humidity- and
light-controlled conditions. Mice were initially fed ad
libitum with standard mouse chow and water and were
allowed to acclimate for 1 week prior to surgery. During
the administration of intravenous solutions, mice were
housed inmetabolic cages to prevent coprophagia. Studies
conformed to guidelines for care established by the
University Committee on Use and Care of Animals at the
University of Michigan, and protocols were approved by
that committee (no. 03986).
Methods of cannulation and TPN infusion were
identical to those previously described (Kiristioglu &
Teitelbaum, 1998; Wildhaber et al. 2003; Yang et al.
2007). The control group received intravenous crystalloid
solution at 0.2 ml h−1 and standard laboratory mouse
chow. TheTPNgroups received intravenous TPN solution
at 4.8 ml (24 h)−1. All animals were killed at 7 days using
CO2.
Male TNFR1R2DKO (Tnfrsf1atm1Imx Tnfrsf1btm1-
Imx/J), TNFR1KO (Tnfrsf1atm1Imx/J) and TNFR2KO
(Tnfrsf1btm1Mwm/J) mice were used in this study. All
mice had a C57BL6 background (Jackson Laboratories);
body weight and age were matched to wild-type (WT)
mice (Feng & Teitelbaum, 2012). In some experiments,
both WT control and TPN groups were injected intra-
venously with recombinant mouse TNF-α (rmTNF,
200 ng (g body weight)−1; ImmunoTools, Friesoythe,
Germany) 3 h before they were killed (Gunther et al.
2011). In another group of TPN and enterally fed
groups, WT mice were given 200μg (kg body weight)−1
of Etanercept (Immunex Corporation,Thousand Oaks,
CA, USA) subcutaneously every 48 h for three doses, and
another dose of 500μg (kg body weight)−1 was given 3 h
before they were killed (Fries et al. 2008; Nemoto et al.
2011).
Intestinal epithelial resistance and permeability
measurements
Ussing chambers (Physiologic Instruments, Inc., San
Diego, CA, USA) were used to assess full-thickness
proximal small intestinal (6 cm from the ligament of
Treitz) barrier function (Yang et al. 2002). Transepithelial
resistance (TER) was measured after a 3 min equilibration
and determined using Ohm’s Law (Reims et al. 2006).
Permeability of the small intestine was assessed with
fluorescein isothiocyanate (FITC)–dextran (4000 kDa at
50mgml−1; Sigma-Aldrich) as a tracer molecule (Bu¨cker
et al.2011). For this, 150μl FITC–dextranwas added to the
mucosal compartment of Ussing chambers after 30min
equilibration, and 500μl of buffer was taken from the
serosal compartment 2 h after incubation for analysis the
FITC–dextran concentration. Fluorescence was measured
using a Synergy 2Multi-ModeMicroplate Reader (BioTek,
Winooski, VT,USA) at an excitationwavelength of 492 nm
and an emission wavelength of 515 nm. Permeability
was expressed as the mucosal-to-serosal clearance of
FITC–dextran-4000 (Bu¨cker et al. 2011).
Western blotting
For protein analysis, IECs were isolated from the small
intestine using a modification of Grossmann’s technique.
Intestinal epithelial cells were used to prepare protein
lysates for Western blotting; techniques were as pre-
viously described (Grossmann et al. 1998; Schwarz et al.
2007). The purity of the epithelial isolates was assessed
by microscopic inspection at isolation and Western blot
analysis for E-cadherin and smooth muscle actin (not
shown); the epithelial isolates consisted primarily of
intact released crypts that were E-cadherin positive and
smooth muscle actin negative. Blots were stripped and
reprobed with monoclonal mouse anti-β-actin antibody
to confirm equal loading of protein. The results are
expressed as the ratio of relative protein expression to
β-actin expression. The antibodies used for immunblots
were as follows: rabbit anti-ZO-1 andmouse anti-occludin
(Life Technologies Corporation, Carlsbad, CA, USA);
mouse anti-E-cadherin (BD, San Jose, CA, USA); mouse
anti-IκBα and mouse anti-phosphate MLC (p-MLC; Cell
Signalling, Danvers, MA, USA); and mouse anti-β-actin
(Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Secondary antibody was either goat anti-mouse-HRP or
goat anti-rabbit-HRP (Santa Cruz).
Immunofluorescence microscopy
A 0.5 cm section of fresh jejunum (∼10 cm from
the ligament of Treitz) was harvested, and immuno-
fluorescence staining was performed as previously
C© 2013 The Authors. The Journal of Physiology C© 2013 The Physiological Society
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described (Feng et al. 2009; Nose et al. 2010). Fluorescence
was analysed by using an Olympus BX-51 upright light
and fluorescence microscope. Images were stacked using
Nikon image software and processed using Adobe Photo-
shop CS4.
Data analysis
Data were expressed as means± SD. Statistical analysis
employed Student’s paired t tests for comparison of
two means, a one-way ANOVA for comparison of
multiple groups (with a Bonferoni post hoc analysis
to assess statistical differences between groups) and a
two-way ANOVA for categorical data (Prism software;
GraphPad Software, Inc., San Diego, CA, USA). Statistical
significance was defined as P < 0.05.
Results
Total parenteral nutrition-associated barrier
dysfunction is dependent on TNF-α receptor signalling
In order to begin to address the dependence of TNF-α
receptors on TPN-associated loss of EBF, a series of
TNFR1R2DKO and TNFR1 or TNFR2 single KO mice
were used. It has been demonstrated previously that
enteral nutrient deprivation leads to a loss of EBF (Yang
et al. 2009; Nose et al. 2010; Hagiwara et al. 2011; Feng
et al. 2012). This present study confirmed that after
7 days of TPN, TER was decreased 1.6-fold compared
with enteral controls (Fig. 1A). Additionally, permeation
of FITC–dextran to the serosal side increased 7-fold vs.
controls (Fig. 1B).
Transepithelial resistance was then examined in TNF
receptor KO mice. Interestingly, the use of TNFR1KO
resulted in partial prevention of the loss of TER (58.6%
of enteral control mice), whereas TNFR2KO mice had
no impact on the restoration of TER. However, use of
TNFR1R2DKO mice further improved TER compared
with WT TPN mice (72.7% of control levels), and
TER rose significantly above that of TNFR1KO mice
(14.1% further improvement in TER). Examination
of FITC–dextran permeability showed similar results,
with some important distinctions. Both TNFR2KO and
TNFR1KO mice given TPN had a significant 50 and 61%
reduction (respectively) in permeation compared with
wild-type mice. Importantly, the use of TNFR1R2DKO
mice led to a complete restoration of permeability levels,
which were essentially the same as those of enterally
fed mice (Fig. 1B). This suggests that both the TNFR1
and TNFR2 signalling pathways have important roles in
mediating EBF loss, and this was explored further. When
examining TER and FITC–dextran permeation in all
control groups, there was no difference between wild-type
mice and other strains (data not shown).
B
A
0 15 30 45 60 75 90
10
15
20
25
30
35
40
 Control
WT TPN
TNFR1KO TPN
TNFR1R2DKO TPN
TNFR2KO TPN
Time (minutes)
TE
R
 (Ω
.
cm
2 )
*
*
*
*
** **
*
ns
ns
Co
ntr
ol
TP
N
TN
FR
1R
2D
KO
 TP
N
TN
FR
1K
O T
PN
TN
FR
2K
O T
PN
0
5
10
15
20
FI
TC
-D
ex
tra
n 
( μg
/m
l)
Figure 1. Total parenteral nutrition (TPN)-associated barrier
dysfunction is dependent on integrity of receptors TNFR1 and
TNFR2
A, transepithelial resistance (TER) measurements were performed in
Ussing chambers. The results are the mean of a minimum of 6 mice
per group over 90 min, preceded by a 30 min equilibration period.
Note that TPN administration led to a 50% decrease in TER vs.
controls in wild-type (WT) mice. This decline was partly prevented in
TNFR1 knockout (KO) mice, but only slightly in TNFR2KO mice.
However, TNFR1R2 double knockout (DKO) mice showed significant
prevention of the reduction in TERvs. other TPN groups.
B, paracellular permeability was measured by the mucosal to serosal
passage of FITC–dextran. Administration of TPN led to a marked
increase in FITC–dextran permeation in WT mice. This increase in
permeability was partly prevented in either TNFR1KO or TNFR2KO
TPN mice and almost completely prevented in TNFR1R2DKO mice.
∗P < 0.05, ∗∗P < 0.01.
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Total parenteral nutrition-associated loss of tight
junction and adherence junction protein expression
was prevented in TNFR1R2DKO mice
The tight junction proteins ZO-1 and occludin were
measuredwith immunoblotting and immunofluorescence
staining. Similar to our previous publication (Sun et al.
2008; Nose et al. 2010), expression of ZO-1 and occludin
protein decreased significantly with administration of
TPN (Fig. 2A and B). The effect of TNFR1 and TNFR2
on the abundance of these tight junction proteins was
then investigated. The results of Western blots showed
that ZO-1 and occludin remained markedly decreased in
TNFR2KO, and amounts were not significantly greater
than WT TPN levels. Use of TNFR1KO TPN mice partly
prevented the loss of these junctional proteins; however,
use of TNFR1R2DKOTPNmice completely prevented the
loss of these proteins (Fig. 2A and B).
Immunofluorescence staining showed a clear and sharp
expression of ZO-1 and occludin along the surface of
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Figure 2. Deletion of both TNFR1 and TNFR2 prevents TPN-associated tight junction protein down-
regulation
Expression of zonula occludens-1 (ZO-1) and occludin was measured with Western immunoblots and immuno-
fluorescence staining. The mean ratios of these proteins to β-actin are reported for a minimum of at least n = 6 per
group. ∗∗P < 0.01, ∗P < 0.05. A, representative example of immunoblots and relative density to β-actin. B, ZO-1
and occludin protein levels declined with TPN, and this decline was totally prevented in TNFR1R2DKO TPN mice.
A partial prevention was seen in TNFR1KO TPN mice, but no change was observed in the TNFR2KO TPN group.
C, immunofluorescence staining showed decreased ZO-1 (red) and occludin expression (green) with TPN. This was
almost completely prevented in TNFR1R2DKO mice (Cc, g and m) and partly prevented in TNFR1KO mice (Cf , i
and n), but was not changed in TNFR2KO mice (Ce, j and o). D, High-magnification images showing that the
co-localization of ZO-1 and occludin (yellow; Da) was lost in WT TPN mice (Db), with an internalization of occludin
(∗). This co-localization was nearly completely recovered in TNFR1R2DKO mice (Dc). Diffuse ZO-1 expression and
occludin internalization persisted in TNFR1KO mice (Dd); and use of TNFR2KO mice produced similar results to
those for WT TPN mice.
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epithelial cells in enterally fed mice (Fig. 2Ca and f ),
which was lost with enteral deprivation (Fig. 2Cb and
g). The co-localization of these two proteins was found
in the enterally fed group, but was lost in TPN mice
(Fig. 2Da and b). Administration of TPN resulted in
disassembly of ZO-1 and occludin, along with an inter-
nalization of occludin within the cytoplasm (asterisks in
Fig. 2Db,), consistent with other models where TNF-α is
given exogenously (Shifflett et al. 2005; Clayburgh et al.
2006; Tang et al. 2010). Use of TNFR1KO or TNFR2KO
mice did not prevent this loss. However, the loss of
intensity of ZO-1 along the epithelial surface was partly
prevented in TNFR1KOTPNmice. Use of TNFR1R2DKO
TPNmice resulted inavirtually completepreventionof the
loss of ZO-1 and occludin expression at the tight junction
complex. At high magnification (Fig. 2D), occludin
expression, TJ assembly and co-localization of these two
proteins was protected in TNFR1R2DKO TPN mice (Fig.
2D, III). Zonula occludens-1 expression and localization
within the tight junction complex was partly recovered in
TNFR1KO TPN mice. However, ZO-1 was more diffusely
expressed along the epithelial surface, and an inter-
nalization of occludin was still observed in TNFR1KO
TPN mice (Fig. 2Dd). Total parenteral nutrition given
to TNFR2KO mice failed to prevent the loss of ZO-1
and cccludin expression and junctional disassembly
(Fig. 2De).
Thus, although TNFR2KO mice failed to show
an improvement in TER and TJ integrity, an inter-
nalization of TJs and loss of TER persisted until both
TNFR1 and TNFR2 were eliminated, demonstrating
the importance of both the TNF-α signalling
pathways.
The expression levels of claudin-1, -2 and -4 were
measured with Western immunoblots. Administration of
TPN led to a significant downregulation in claudin-1
expression (2-fold vs. enteral controls). This decline
was prevented in TNFR1R2DKO and TNFR1KO mice,
but not in TNFR2KO mice (Fig. 3A and B). Total
parenteral nutrition did not obviously affect the protein
expression of claudin-2 in WT mice. Interestingly,
claudin-2 expression was upregulated 2.5-fold above
enteral controls in the TNFR1R2DKO TPN group;
however, claudin-2 expression was not affected in TNFR1
or TNFR2 single KO TPN groups (Fig. 3A and C).
Total parenteral nutrition-associated downregulation of
claudin-4 expression was decreased in WT TPN mice,
and expression was somewhat reduced with the use of
TNFR1R2DKO mice.
Zonula occludens-1 acts as a functional cross-linker
between the E-cadherin–catenin complex and the
actin-based cytoskeleton (Itoh et al. 1997; Shen, 2012).
We have previously reported (Feng et al. 2009) that
the abundance of E-cadherin protein was significantly
decreased with TPN in WT mice. In the present study,
the decrease in E-cadherin protein expression assessed by
immunoblotting was totally prevented in TNFR1R2DKO
TPN mice; however, the use of TNFR1 or TNFR2 single
KO mice did not affect the loss of E-cadherin expression
(Fig. 4A and B).
Co-localization of ZO-1 and E-cadherin was also
measuredwith immunofluorescence staining. E-Cadherin
was expressed along the surface and between IECs in
the control group; furthermore, a tight co-localization
of ZO-1 and E-cadherin was observed at the IEC
apical surface (Fig. 4Ca and f ). The expression levels
of both ZO-1 and E-cadherin were markedly decreased
in WT TPN mice, and TPN also led to a loss of
co-localization of these proteins (Fig. 4Cb and g). Use
of TNFR1R2DKO mice prevented this TPN-associated
loss of E-cadherin expression and maintained ZO-1 and
E-cadherin co-localization (Fig. 4Cc and h). However, the
useof singleTNFR1KO(Fig. 4Cd and i)orTNFR2KOmice
(Fig. 4Ce and j) failed toprotect E-cadherin expression and
assembly in TPN mice. Thus, the loss of the adherence
junction integrity appears to be dependent on TNFR1 and
TNFR2 signalling.
Total parenteral nutrition-associated upregulation of
myosin light chain activation and nuclear factor-κB
(NF-κB) signalling is TNF receptor dependent
Activation of themyosin light chain pathway iswell known
to play a critical role in tight junction regulation in
intestinal (Clayburgh et al. 2005; Ye et al. 2006) and lung
epithelial monolayers (Dull et al. 2003). In addition, in
inflammatory bowel disease models (Su et al. 2009;Weber
et al. 2010;Gilbert et al. 2012), the activation ofMLCvia its
phosphorylation has been shown to be responsible for the
internalization of junctional proteins, including occludin,
and is one of the key mechanisms for the loss of barrier
function. Phosphorylated MLC (p-MLC) expression
(measured via immunoblots) showed that TPN led to an
upregulation of p-MLC expression by 3-fold vs. controls
(Fig. 5A andB). Interestingly, this upregulationwas totally
prevented in TNFR1R2DKO TPN mice. However, both
TNFR1KO and TNFR2KO TPN mice maintained high
expression of p-MLC, demonstrating the importance that
both receptors have in driving this mechanism of EBF
loss.
Activation of NF-κB in IECs can lead to production
of pro-inflammatory cytokines and chemokines that
secondarily recruit immunocytes, thereby initiating an
inflammatory amplification cascade (Barnes & Karin,
1997). Nuclear factor-κB is regulated by its release from
activated (phosphorylated) by IkB kinase (IKK) complex
consisting of the IKBα and IKBβ catalytic subunits
C© 2013 The Authors. The Journal of Physiology C© 2013 The Physiological Society
J Physiol 591.15 Intestinal barrier function in total parenteral nutrition 3715
and the IKKγ/NEMO regulatory subunit (DiDonato
et al. 1997; Rothwarf & Karin, 1999; Ghosh & Karin,
2002). To examine activation of NF-κB, IKBα expression
was measured with immunoblotting (Fig. 5A and C).
Total parenteral nutrition significantly decreased IKBα
protein expression (3.8-fold vs. WT controls), indicating
TPN-driven NF-κB activation. Expression IKBα protein
was totally prevented in TNFR1R2DKO TPN mice, and
levels returned to control values. A partial prevention
of the decline in IKBα was seen in the TNFR1KO and
TNFR2KO TPN mice.
Anti-tumour necrosis factor treatment prevented
TPN-associated loss of epithelial barrier function, and
exogenous TNF-α further impaired barrier function
Etanercept, an engineered TNFR2 protein that acts as
a TNF-α antagonist by competitively binding soluble
TNF-α, was used to study the effect of blocking end-
ogenous expression ofTNF-α. Etanercept treatment partly
prevented the TPN-associated decline in small bowel
TER (17± 2.12 vs. 12.6± 0.89 cm2, TPN+ Etanercept
vs. TPN+ isotype IgG control; P < 0.01; Fig. 6A).
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Figure 3. Claudin abundance is regulated by TNFR1 and TNFR2 signalling in mice receiving TPN
The expression levels of claudins-1, -2 and -4weremeasuredwithWestern blotting in each group (n ≥ 6 per group).
A, representative immunoblots and density expressed relative to that of β-actin. B–D, abundance of claudin-1, -2
and -4 proteins in each study group. Claudins-1 and -4 declined in TPN mice. The decline in claudin-1 was
partly prevented in TNFR1KO mice, and both claudin-1 and claudin-4 were restored to nearly the same levels as
the control values in TNFR1R2DKO. Note that claudin-2 expression was not affected by TPN, but was markedly
upregulated in TNFR1R2DKO TPN mice. ∗P < 0.05, ∗∗P < 0.01.
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Examination of permeability also showed that Etanercept
treatment significantly decreased mucosal to serosal
passage of FITC–dextran (8.79 ± 1.29 vs. 13.18 ±
3.22 μg ml−1, TPN+ Etanercept vs. TPN+ isotype IgG
control; P < 0.001; Fig. 6B). Etanercept treatment did
not affect TER and permeablity in enteral-fed groups
(data not shown). Zonula occludens-1, occludin and
E-cadherin expression were significantly increased after
Etanercept treatment vs. isotype IgG treatment in TPN
mice (Fig. 6C andD). Furthermore, immunofluorescence
staining showed a partial prevention in the loss of
co-localization and distribution of ZO-1/occludin and
ZO-1/E-cadherin with Etanercept treatment (Fig. 6E
and F). Etanercept treatment also partly prevented the
TPN-associated increase in NF-κB and MLCK activation,
bringing p-MLC and IKBα expression close to control
levels (Fig. 6C and D).
In order to examine the effect of TNF-α further in
this TPN model, exogenous recombinant mouse TNF-α
(rmTNF) was injected intravenously in WT control and
TPN mice 3 h before the mice were killed. The TER
values decreased significantly after rmTNF injection.
Transepithelial resistance declined to 16.9± 4.8 cm2
in the enteral-fed control group with rmTNF treatment
compared with 26.5± 2.7 cm2 in control mice given
saline (P < 0.001; Fig. 7A). In addition, TER decreased
to 5.35± 0.73 cm2 in WT TPN+ rmTNF mice,
which was significantly lower than the TER seen in WT
TPN+ saline mice (13± 1.19 cm2). This trend was
also seen with permeability data. Serosal FITC–dextran
concentration increased (8.42± 1.48μgml−1) in control
mice treated with rmTNF vs. saline (2.25± 0.94μgml−1;
P < 0.001). In the TPN group, rmTNF further increased
FITC–dextran concentration (19.41± 8.41μgml−1,
compared with 16.59± 5.14μgml−1 in TPN mice
without rmTNF), but the difference was not significant
(Fig. 7B). Zonula occludens-1 and occludin expression
measured by immunoblotting were not affected in control
and TPN groups after rmTNF (Fig. 7C). However,
compared with saline injection, immunofluorescence
staining showed that the assembly of ZO-1, occludin
and E-cadherin was markedly deranged with rmTNF
injection to a greater degree than in WT TPN mice
(Fig. 7D and E). In enteral controls, exogenous rmTNF
disrupted ZO-1 and occludin distribution (Fig. 7Da and
c) and also disrupted the co-localization of ZO-1 with
E-cadherin (Fig. 7Ea and c). Furthermore, exogenous
rmTNF injection totally abolished ZO-1 and occludin
expression, and led to a further decline in E-cadherin
expression, resulting in a markedly disrupted TJ and
adherens junction assembly in TPN mice (Fig. 7Da and
d, Fig. 7Ea and d).
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fluorescence staining. ∗∗P < 0.05, ∗P < 0.01. A, representative Western blots and density expressed relative to
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Discussion
Total parenteral nutrition is vital for the supportofpatients
who cannot tolerate enteral nutrition. It is estimated
that over 350,000 patients yearly in the USA receive
TPN, resulting in over 11.5 million patient days of
care each year; a number which has almost doubled in
the past 20 years (HCUPnet, 2010). Unfortunately, TPN
results in both morphological and functional changes to
the intestinal epithelium, including intestinal epithelial
cell apoptosis, loss of IEC proliferation and a loss of
EBF (Feng et al. 2009; Feng & Teitelbaum, 2012). Total
parenteral nutrition-associated barrier dysfunction has
been reported in humans and rodent models (Buchman
et al. 1995; Kansagra et al. 2003; Sun et al. 2008; Nose et al.
2010), and may result in endotoxins and even bacteria
entering the systemic circulation.
The formation and maintenance of an intact intestinal
barrier is critical to maintain normal physiological
function and prevent diseases, such as ulcerative colitis,
Crohn disease, chronic diarrhoeal disease and other
infectious and inflammatory intestinal diseases (Meddings
et al. 1994). Significant data suggest that TNF-α is involved
in the dysregulation of intestinal EBF (Lorenzo-Zu´n˜iga
et al. 2006; Kolodziej et al. 2011; Marchiando et al. 2011;
Noth et al. 2011; Scharl et al. 2011; Ye et al. 2011) and is
a critical pathogenic component of many related diseases.
Tumour necrosis factor-α and other pro-inflammatory
factors, such as interferon-γ, are major factors which
contribute to TPN-associated loss of EBF. Anupregulation
of small intestinal TNF-α and TNFR1 expression was
identified in our TPN mouse model and was closely
linked with loss of IEC proliferation and an increase in
IEC apoptosis (Feng & Teitelbaum, 2012). Researchers in
our laboratory previously reported that TPN-associated
loss of small intestinal EBF was partly prevented using
interferon-γ KO mice; however, the role of TNF-α has
not been investigated. Importantly, this TPN model is
a very useful tool to examine the role of the TNF-α
signalling pathway in the loss of intestinal EBF, as well as
the mechanisms and signalling pathways used by TNF-α.
Unlike other models, which rely on a mucosal injury, such
as chemical-induced mucosal injury or exogenous TNF-α
(Clayburgh et al. 2005), the TPN model offers a unique
A, representative images of p-MLC and IKBα Western blots, as well
as total MLC and β-actin. B, mean expression of p-MLC in
relationship to total MLC. Total parenteral nutrition upregulated
p-MLC expression, and this was prevented in TNFR1R2DKO mice,
and only partly in TNFR1KO mice, but not in TNFR2KO mice. C, IKBα
expression relative to β-actin showed that TPN administration led to
a marked loss of IKBα expression. Use of TNFR1KO or TNFR2KO TPN
mice partly prevented this decline, and loss of IKBα expression was
totally prevented in TNFR1R2DKO TPN mice.
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approach to study the effects of these pro-inflammatory
cytokines in a very clinically relevant setting. Importantly,
while TPN administration did lead to mucosal atrophy,
due to epithelial cell apoptosis and loss of proliferation, it
was not associatedwith anymajor erosions of the epithelial
lining. In order to understand better how TPN-associated
EBF loss occurs, we sought to determine whether one
or both TNF receptors were necessary for TNF-induced
barrier dysfunction. In the present study, we showed
that TPN-associated loss of EBF was dependent on both
TNFR1 and TNFR2, and that without blocking both
signalling pathways EBF loss was incompletely prevented.
This finding shows, for the first time, that both TNFR1
and TNFR2 signalling play an important role inmediating
intestinal epithelial barrier dysfunction.
In inflammatorybowel disease,modulationof intestinal
epithelial MLCK expression and its activation of MLC to
phospho-MLC play a critical role in the mechanisms that
result inEBF loss (Chen et al.2012;Cunningham&Turner,
2012; Gilbert et al. 2012). Our study showed that TPN
led to increased p-MLC expression in IECs and that this
was totally prevented in TNFR1R2DKO mice, but not in
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Figure 6. Etanercept treatment prevents TPN-associated loss of epithelial barrier function
Wild-type TPN mice were given 200 μg (kg body weight)−1 of the tumour necrosis factor-α (TNF-α) antagonist
Etanercept subcutaneously, every 48 h for three doses, with another dose of 500 μg kg−1 given 3 h before the
mice were killed. Controls were WT TPN mice given istotype IgG. ∗P < 0.05, ∗∗P < 0.01. A, Etanercept prevented
the TPN-associated decline in TER. B, Etanercept also prevented the TPN-associated increase in permeability to
FITC–dextran. C, representative Western blots from isolated IECs. D, protein abundance of ZO-1, occludin and
E-cadherinmeasured by immunoblots relative to β-actin. The junctional protein abundance showed that Etanercept
treatment prevented loss of the junctional proteins. Etanercept also prevented the rise in p-MLC and decline in
IKBα. E and F, ZO-1, occludin and E-cadherin immunofluorescence staining. Prevention by Etanercept of the loss of
junctional proteins is also seen by immunofluorescence staining. Note also the preservation of both ZO-1/occludin
and ZO-1/E-cadherin co-localization (white arrows).
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TNFR1orTNFR2 singleKOTPNmice. This demonstrates
a critical need for both TNFR1 and TNFR2 signalling to
mediate this downstream p-MLC expression in vivo.
Nuclear factor-κB is a major downstream signalling
factor following TNF-α signalling, and activation of
NF-κB could be one of themechanism leading to increased
epithelial permeability (Kisseleva et al. 2006; Chen et al.
2008) and tight junction dysfunction (Wachtel et al. 2001).
Recently, NF-κB binding motifs were demonstrated to
be present on the MLCK promoter region, and these
served as a regulatory site to induceMLCK gene activation
(Ye & Ma, 2008). In the present study, we showed
that TPN administration resulted in an upregulation of
NF-κB activation, and that blockade of either TNFR1
or TNFR2 was insufficient to prevent NF-κB activation.
Activation of NF-κB was completely blocked only in
TNFR1R2DKO TPN mice or with the use of Etanercept.
This further emphasizes the importance of both TNF
signalling pathways in driving NF-κB activation and
MLCK signalling in this model.
The claudins are a large family of transmembrane
adhesion proteins located at intercellular tight junctions
(Zeissig et al. 2007). A considerable number of studies have
demonstrated that claudins can modulate TER through
regulation of ionic charge selectivity (Van Itallie et al.
2001; Amasheh et al. 2002; Colegio et al. 2002; Spring,
2002), providing convincing evidence that claudins line
the paracellular pores. Claudin-1 and claudin-4 provide
strength to the epithelial barrier, and both were markedly
downregulated in TPN mice; and this loss was partly
prevented in TNFR1R2DKO mice. Claudin-2 has been
identified as an electrically ‘leaky’ claudin (Furuse et al.
2001; Amasheh et al. 2002; Holmes et al. 2006) and is
concentrated in intestinal crypts (Holmes et al. 2006),
where larger paracellular pores have been reported
(Marcial et al. 1984). Administration of TPN did not
affect claudin-2 expression. In fact, surprisingly, a higher
expression of claudin-2 was observed in TNFR1R2DKO
TPN mice compared with the other groups. As available
data suggest that it is the pattern of claudin isoform
expression that defines tight junction charge selectivity
(Simon et al. 1999; Van Itallie et al. 2001), TNF-α may
act by globally removing claudins from the tight junction
complex, and not by altering the expression of specific
claudin isoforms. It is possible that in the absence of
TNF-α signalling in TNFR1R2DKOTPNmice, a normally
counter-regulatorymechanism between TNF-α signalling
and claudin-2 may be disrupted.
Anti-tumour necrosis factor treatment was used as an
alternative approach to block TNF-α signalling. Use of
Entanercept, a modified TNFR2 that binds competitively
to circulating TNF-α, partly prevented TPN-associated
barrier loss. Conversely, exogenous TNF-α treatment led
tomarked exacerbation in IEC barrier dysfunction in both
control and TPNmice (greater than that of untreated TPN
mice). These findings further demonstrate that TNF-α
signalling plays a critical role in the TPN-associated
IECbarrier dysfunction.However, neither TNFR1R2DKO
nor anti-TNF treatment completely prevented barrier
dysfunction in TPN mice. This suggests that TNF-α
is most likely not to be the only factor involved
in this mechanism. Clearly, the actions of other
pro-inflammatory cytokines that are expressed in excess
during TPN administration should be considered. It has
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Figure 7. Administration of TNF-α increased the loss of barrier function in wild-type mice receiving TPN
Wild-type enterally fed (control) mice or mice receivingTPN were treated with either saline or recombinant mouse
TNF-α (rmTNF, 200 ng (g body weight)−1) given I.V. 3 h before the end of the 7 day study period. ∗P < 0.05,
∗∗P < 0.01. A, note a further decline in TER with exogenous TNF-α. B, FITC–dextran showed a further increase in
permeability with TNF-α. C, Western blots. D and E, immunofluorescence staining showed that rmTNF-α treatment
led to a further loss in ZO-1, occludin and E-cadherin staining intensity for both control and TPN groups.
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been reported that interferon-γ has an important role in
modulating gut barrier function, which could contribute
to TPN-associated barrier dysfunction either dependent
onor independentofTNF-α signalling.Also, interleukin-6
expression was shown to be upregulated in our TPN
model (Wildhaber et al. 2005), and this cytokine can
also negativelymodulate intestinal tight junction function
(Suzuki et al. 2011; Jonker et al. 2012). Therefore, a further
exploration of the cross-talk among these cytokines will
be needed in future studies.
Although using a distinctly different approach, these
findings were different from those previously reported
(Wang et al. 2006). In the detailed report by Wang et al.
(2006), interferon-γ priming increased TNFR2 expression
and resulted in loss of EBF. Furthermore, this action
was independent of the TNFR1 signalling pathway. The
distinction between those findings and the present report
may be due to the fact that our study used an in vivomodel,
whereas their study used an in vitro approach. The TPN
model allows for a variety of other factors that may be
interdependent on an intact TNF-α signalling pathway.
For example, TNF-α and ErbB signalling demonstrate
a tight interdependence (Yamaoka et al. 2008). In our
TPN mouse model, TNF-α and ErbB signalling were
markedly unbalanced, with an increase in TNF-α and
loss of ErbB signalling (Feng et al. 2011). This loss in
ErbB signalling is a key factor associated with loss of IEC
proliferation and increased IEC apoptosis, and was pre-
vented in the present reportwith the use of TNFR1R2DKO
mice.
One of the shortcomings of the present work is that
we used whole-animal knockouts (TNFR1 and TNFR2)
for our studies. Thus, we have not fully dissected out
the potential interaction of TNFR signalling between the
myeloid and epithelial cell populations. Unfortunately,
there are no epithelial specific knockouts readily available,
but future studies could address this with the development
of such mice or with the use of bone marrow chimera
studies. One of the other limitations of the present study
was the fact that we are using a single strain of mice,
C57BL/6. While we have studied this strain extensively,
we do acknowledge that the use of other mouse strains,
which have different immune phenotypes, might yield
potentially different responses. Finally, administration of
TPN leads to mucosal atrophy, due to IEC apoptosis
(Feng & Teitelbaum, 2012). It is possible that apoptosis
itself might be a contributory factor to the loss of
EBF.
In conclusion, our study demonstrated that TNF-α
is a critical factor for TPN-associated epithelial barrier
dysfunction. Importantly, we demonstrated that both
TNFR1 and TNFR2 receptors were involved in the
loss of EBF. Furthermore, both MLCK and NF-κB
signalling appear to be important downstream mediators
involved in this TNF-α signalling process. The importance
of these findings may extend well beyond this TPN
model and may help to guide future therapies for a
number of inflammatory processes in the gastrointestinal
tract.
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